Entera Bio, a large-molecule drug spinout of DNA Biomedical Solutions, intends to raise up to $50m when it goes public.

Immunotherapy developer Arcus Biosciences has raised series C funding from a GV-led consortium that included Celgene and Taiho.

Amgen Ventures contributed to a series B round for Fortuna Fix, which will use the funding for clinical trials and to expand manufacturing.

EMBL-backed Arsanis hopes to sell 3,125,000 shares priced at $15 to $17 and raise a total of up to $61m in its initial public offering.

Bonnier has returned to back the fertility tracking app developer's series B round, the proceeds of which will fund international growth.

The US Department of Justice and the SEC are investigating Outcome Health for fraud while investors including Alphabet are suing the company.

The immunoassay instrument developer is targeting $57.5m in an offering that will provide exits for BioMerieux and Stratec Biomedical.

The healthcare provider's hospitals have committed $105m to its Partners Innovation Fund, and it has raised $66.1m from external backers for another fund.